Incidence of Complications of Peripheral Venous Access in the Type 2 Diabetic Population

NCT ID: NCT04499638

Last Updated: 2025-02-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

350 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-01-01

Study Completion Date

2021-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Diabetes Mellitus type 2 (T2DM) is one of the most frequent metabolic diseases worldwide. It is expected that in 2035 around 600 million people will suffer from the disease. A recent systematic review has estimated that the direct annual cost of Diabetes worldwide treatments and care is over $ 827 billion and has been independently associated with nosocomial complications, thrombosis-like infections and prolonged admissions. In addition, it is estimated that up to 90% of patients in acute hospitals require a peripheral venous catheter which are associated at the same time with mechanical, infectious and thrombotic acute complications. Recently the emergence of new medium-sized peripheral devices (Midline®) and new peripheral central venous access catheters (PICC), which are more biocompatible, are opening new clinical possibilities with the aim of improving safety and comfort during treatment time and the reduction of associated complications.

With all this, an observational case-control study has been proposed in order to analyse the impact of T2DM disease and its associated complications on the patient requiring peripheral venous access. Furthermore investigators will consider if these new peripheral devices can be a remarkable benefit for these patients. This study will be carried out at the Vall d'Hebron University Hospital in Barcelona, Spain

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This Prospective case-control study will be carried out with patients that will be admitted in the hospitalization areas of the Vall d'Hebron Hospital. All research data will be collected by the hospital's vascular access nursing team. Complications related to peripheral venous access (phlebitis, thrombosis, pain, erythema, extravasation) and the time of catheter replacement are the focus outcomes of the present study and possible differences between the control group and the sample population of the T2DM will be analysed. General clinical and anthropometric data (age, sex, BMI, toxic habits,...), cause of admission, co-morbidities, and all variables related to diabetes (time of evolution, degree of glycemic control, treatment, and presence of chronic complications) will also be collected. If there are any significant differences, they will be related to the different risk factors associated with T2DM through association of different epidemiological variables. Furthermore in this hypothetical case, the research team would intend to develop and carry out molecular studies through analysis of blood and urine components, proteinomics and genetic studies.

Hypothesis:

* T2DM is an independent risk factor for catheter-related complications.
* The use of new vascular access devices (Midline, PICC) in patients with T2DM would be associated with a lower risk of catheter-related complications.

Main objective:

\- To assess the influence of T2DM on complications related to peripheral vascular catheters in hospitalized patients.

It is expected to colect information of N=500 samples, 250 control group (noT2DM subjects) and 250 study group (T2DM subjects). Due to previous experience, the sample proposed is totally acceptable

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2 Catheterization, Peripheral Upper Extremity Deep Vein Thrombosis Catheter-Related Infections Diabetes Complications

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non type 2 diabetic patient

Tracking the catheter from insertion to removal. Collection of any patients complication associated with these devices and what different treatments has been administered

Peripheral vascular catheters

Intervention Type DEVICE

Carry time of common peripheral vascular devices in clinical practice and the reason for his withdrawal

Diabetic type 2 patient

Tracking the catheter from insertion to removal.Collection of any patients complication associated with these devices and what different treatments has been administered

Peripheral vascular catheters

Intervention Type DEVICE

Carry time of common peripheral vascular devices in clinical practice and the reason for his withdrawal

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Peripheral vascular catheters

Carry time of common peripheral vascular devices in clinical practice and the reason for his withdrawal

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Short canula, Midline, PICC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Peripheral venous access requirement \>7 days
* Administration of intravenous treatment

Exclusion Criteria

* Peripheral venous access for urgent or life-threatening pathology
* Acute psychiatric pathology
* Impossibility of peripheral venous access through the upper limb (amputations, extensive burns, etc.)
* History of venous thrombosis due to catheter less than 1 year
Minimum Eligible Age

40 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital Universitari Vall d'Hebron Research Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rafael Simó, Prof.

Role: STUDY_DIRECTOR

Vall Hebron Research Institute-VHIR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Vall d'Hebron Research Institute-VHIR

Barcelona, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

References

Explore related publications, articles, or registry entries linked to this study.

Nowotny K, Jung T, Hohn A, Weber D, Grune T. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules. 2015 Mar 16;5(1):194-222. doi: 10.3390/biom5010194.

Reference Type BACKGROUND
PMID: 25786107 (View on PubMed)

Asmat U, Abad K, Ismail K. Diabetes mellitus and oxidative stress-A concise review. Saudi Pharm J. 2016 Sep;24(5):547-553. doi: 10.1016/j.jsps.2015.03.013. Epub 2015 Mar 21.

Reference Type BACKGROUND
PMID: 27752226 (View on PubMed)

Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001 May 3;344(18):1343-50. doi: 10.1056/NEJM200105033441801.

Reference Type BACKGROUND
PMID: 11333990 (View on PubMed)

American Diabetes Association. Standards of Medical Care in Diabetes-2017 Abridged for Primary Care Providers. Clin Diabetes. 2017 Jan;35(1):5-26. doi: 10.2337/cd16-0067. No abstract available.

Reference Type BACKGROUND
PMID: 28144042 (View on PubMed)

Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes. 2015 Apr 15;6(3):456-80. doi: 10.4239/wjd.v6.i3.456.

Reference Type BACKGROUND
PMID: 25897356 (View on PubMed)

Hurrle S, Hsu WH. The etiology of oxidative stress in insulin resistance. Biomed J. 2017 Oct;40(5):257-262. doi: 10.1016/j.bj.2017.06.007. Epub 2017 Nov 8.

Reference Type BACKGROUND
PMID: 29179880 (View on PubMed)

Banerjee M, Vats P. Reactive metabolites and antioxidant gene polymorphisms in Type 2 diabetes mellitus. Redox Biol. 2014;2:170-7. doi: 10.1016/j.redox.2013.12.001. Epub 2013 Dec 11.

Reference Type BACKGROUND
PMID: 25460725 (View on PubMed)

Ley SH, Ardisson Korat AV, Sun Q, Tobias DK, Zhang C, Qi L, Willett WC, Manson JE, Hu FB. Contribution of the Nurses' Health Studies to Uncovering Risk Factors for Type 2 Diabetes: Diet, Lifestyle, Biomarkers, and Genetics. Am J Public Health. 2016 Sep;106(9):1624-30. doi: 10.2105/AJPH.2016.303314. Epub 2016 Jul 26.

Reference Type BACKGROUND
PMID: 27459454 (View on PubMed)

Martin-Timon I, Sevillano-Collantes C, Segura-Galindo A, Del Canizo-Gomez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014 Aug 15;5(4):444-70. doi: 10.4239/wjd.v5.i4.444.

Reference Type BACKGROUND
PMID: 25126392 (View on PubMed)

Lowe G, Woodward M, Hillis G, Rumley A, Li Q, Harrap S, Marre M, Hamet P, Patel A, Poulter N, Chalmers J. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes. 2014 Mar;63(3):1115-23. doi: 10.2337/db12-1625. Epub 2013 Nov 12.

Reference Type BACKGROUND
PMID: 24222348 (View on PubMed)

Seuring T, Archangelidi O, Suhrcke M. The Economic Costs of Type 2 Diabetes: A Global Systematic Review. Pharmacoeconomics. 2015 Aug;33(8):811-31. doi: 10.1007/s40273-015-0268-9.

Reference Type BACKGROUND
PMID: 25787932 (View on PubMed)

Sayampanathan AA. Systematic review of complications and outcomes of diabetic patients with burn trauma. Burns. 2016 Dec;42(8):1644-1651. doi: 10.1016/j.burns.2016.06.023. Epub 2016 Aug 29.

Reference Type BACKGROUND
PMID: 27595452 (View on PubMed)

Low ZK, Ng WY, Fook-Chong S, Tan BK, Chong SJ, Hwee J, Tay SM. Comparison of clinical outcomes in diabetic and non-diabetic burns patients in a national burns referral center in Southeast Asia: A 3-year retrospective review; Methodological issues. Burns. 2017 Sep;43(6):1368. doi: 10.1016/j.burns.2017.03.019. Epub 2017 Jun 9. No abstract available.

Reference Type BACKGROUND
PMID: 28602590 (View on PubMed)

Vondran M, Schack S, Garbade J, Binner C, Mende M, Rastan AJ, Borger MA, Schroeter T. Evaluation of risk factors for a fulminant Clostridium difficile infection after cardiac surgery: a single-center, retrospective cohort study. BMC Anesthesiol. 2018 Sep 27;18(1):133. doi: 10.1186/s12871-018-0597-2.

Reference Type BACKGROUND
PMID: 30257648 (View on PubMed)

Keogh S, Marsh N, Higgins N, Davies K, Rickard C. A time and motion study of peripheral venous catheter flushing practice using manually prepared and prefilled flush syringes. J Infus Nurs. 2014 Mar-Apr;37(2):96-101. doi: 10.1097/NAN.0000000000000024.

Reference Type BACKGROUND
PMID: 24583939 (View on PubMed)

Bomberg H, Kubulus C, List F, Albert N, Schmitt K, Graber S, Kessler P, Steinfeldt T, Standl T, Gottschalk A, Wirtz SP, Burgard G, Geiger P, Spies CD, Volk T; German Network for Regional Anaesthesia Investigators. Diabetes: a risk factor for catheter-associated infections. Reg Anesth Pain Med. 2015 Jan-Feb;40(1):16-21. doi: 10.1097/AAP.0000000000000196.

Reference Type BACKGROUND
PMID: 25474624 (View on PubMed)

Liem TK, Yanit KE, Moseley SE, Landry GJ, Deloughery TG, Rumwell CA, Mitchell EL, Moneta GL. Peripherally inserted central catheter usage patterns and associated symptomatic upper extremity venous thrombosis. J Vasc Surg. 2012 Mar;55(3):761-7. doi: 10.1016/j.jvs.2011.10.005.

Reference Type BACKGROUND
PMID: 22370026 (View on PubMed)

Bahl A, Hang B, Brackney A, Joseph S, Karabon P, Mohammad A, Nnanabu I, Shotkin P. Standard long IV catheters versus extended dwell catheters: A randomized comparison of ultrasound-guided catheter survival. Am J Emerg Med. 2019 Apr;37(4):715-721. doi: 10.1016/j.ajem.2018.07.031. Epub 2018 Jul 19.

Reference Type BACKGROUND
PMID: 30037560 (View on PubMed)

Pittiruti M, Brutti A, Celentano D, Pomponi M, Biasucci DG, Annetta MG, Scoppettuolo G. Clinical experience with power-injectable PICCs in intensive care patients. Crit Care. 2012 Feb 4;16(1):R21. doi: 10.1186/cc11181.

Reference Type BACKGROUND
PMID: 22305301 (View on PubMed)

Potet J, Arnaud FX, Thome A, Weber-Donat G, Konopacki J, Bouzad C, Kervella Y, Erauso T, Garcia G, Evelyne P, Valbousquet L, Baccialone J, Teriitehau CA. Peripherally inserted central catheter placement in patients with coagulation disorders: A retrospective analysis. Diagn Interv Imaging. 2015 Nov;96(11):1147-51. doi: 10.1016/j.diii.2014.12.012. Epub 2015 May 27.

Reference Type BACKGROUND
PMID: 26025158 (View on PubMed)

Gao Y, Fan X, Han J. Prognostic factors for venous thrombosis in patients with peripherally inserted central catheters: Protocol for a systematic review and meta-analysis. Medicine (Baltimore). 2020 Jul 10;99(28):e21037. doi: 10.1097/MD.0000000000021037.

Reference Type BACKGROUND
PMID: 32664112 (View on PubMed)

Miliani K, Taravella R, Thillard D, Chauvin V, Martin E, Edouard S, Astagneau P; CATHEVAL Study Group. Peripheral Venous Catheter-Related Adverse Events: Evaluation from a Multicentre Epidemiological Study in France (the CATHEVAL Project). PLoS One. 2017 Jan 3;12(1):e0168637. doi: 10.1371/journal.pone.0168637. eCollection 2017.

Reference Type BACKGROUND
PMID: 28045921 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PR(AG)74/2020

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Safe-Infusion Study
NCT06727240 RECRUITING NA
Midlines and Thrombophlebitis
NCT03725293 COMPLETED NA